U.S. License Holder:
Coherus Biosciences Inc.
Date of License:
LOQTORZI (toripalimab-tpzi) is a programmed death receptor-1 (PD-1)- blocking antibody indicated:
In combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC);
As a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.